Stocks

JPMorgan Raises BeOne Medicines Target Price Amid Bullish Sentiment

Guavy AI Editorial Team Published October 1, 2026

Instruments

JPM

BeOne Medicines (NASDAQ:ONC) has seen its target price raised by JPMorgan Chase & Co. from $425 to $445 in a research note issued on Thursday.

This would suggest a potential upside of 23.34% from the stock's current price, which was $360.79 as of Thursday. The firm's research analysts currently have an 'overweight' rating on the stock.

BeOne Medicines has received upgrades and target price increases from several other firms recently, including Zacks Research, Wolfe Research, Truist Financial, Guggenheim, and Citigroup. These firms have all given the company a buy or overweight rating with various price targets ranging from $370 to $445.

The company's market capitalization is currently at $39.61 billion, with a 50-day moving average of $352.67 and a 200-day moving average of $315.41.

JPMorgan Raises BeOne Medicines Target Price Amid Bullish Sentiment

Ethiopian Airlines Orders Ten Boeing Aircraft to Boost Cargo Capacity

Boeing Secures $20 Billion Contract for Next-Gen Fighter Jet

Starlink Expansion: American Airlines Considers Adding Boeing Fleets